Although the use of PREDICT is recommended to aid decision making in the adjuvant setting8, its prognostic role in HER2-positive early breast cancer patients treated with modern chemotherapy and anti-HER2 therapies remains unclear. The gene discussed is ERBB2; the disease is breast carcinoma.